AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 44.51 USD 0.36% Market Closed
Market Cap: 1.2B USD

AnaptysBio Inc
Long-Term Investments

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

AnaptysBio Inc
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Long-Term Investments
$7.7m
CAGR 3-Years
-63%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Long-Term Investments
$291m
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Investments
$5.7B
CAGR 3-Years
287%
CAGR 5-Years
208%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Investments
$10.3B
CAGR 3-Years
20%
CAGR 5-Years
29%
CAGR 10-Years
31%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
69.95 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Long-Term Investments?
Long-Term Investments
7.7m USD

Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Long-Term Investments amounts to 7.7m USD.

What is AnaptysBio Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
-27%

Over the last year, the Long-Term Investments growth was -72%. The average annual Long-Term Investments growth rates for AnaptysBio Inc have been -63% over the past three years , -27% over the past five years .

Back to Top